Prevalence of hand-foot syndrome following chemotherapy for colorectal cancer: a systematic review and meta-analysis.
Colorectal neoplasms
Hand-foot syndrome
Meta-analysis
Prevalence
Systematic review
Journal
International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899
Informations de publication
Date de publication:
06 Mar 2023
06 Mar 2023
Historique:
accepted:
12
02
2023
entrez:
5
3
2023
pubmed:
6
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
To systematically evaluate the prevalence of hand-foot syndrome (HFS) in patients with colorectal cancer undergoing chemotherapy. The PubMed, Embase, and Cochrane Library databases were searched, from their inception to September 20, 2022, to identify studies on the prevalence of HFS in patients with colorectal cancer receiving chemotherapy. Comprehensive retrieval of literature was performed using the literature tracing method. We calculated the prevalence of HFS in patients with colorectal cancer undergoing chemotherapy based on meta-analyses. Subgroup analysis and meta-regression analyses were performed to determine the sources of heterogeneity. A total of 20 studies were included, involving 4773 cases. Meta-analysis of the random effects model showed that the total prevalence of HFS in patients with colorectal cancer undergoing chemotherapy was 49.1% (95% confidence interval [CI]: 0.332, 0.651). Subgroup analysis demonstrated that the most frequent grades of HFS were grades 1 and 2, accounting for 40.1% (95% CI: 0.285, 0.523) of cases; this rate was markedly higher than that of grades 3 and 4 (5.8%; 95% CI: 0.020, 0.112). The meta-regression results illustrated that the type of research, country of the study population, type of drug, and year of publication were not sources of heterogeneity in this setting (P > 0.05). The present findings showed that the prevalence of HFS in patients with colorectal cancer receiving chemotherapy was high. Healthcare professionals should provide knowledge to such patients regarding the prevention and management of HFS.
Identifiants
pubmed: 36872385
doi: 10.1007/s00384-023-04345-5
pii: 10.1007/s00384-023-04345-5
doi:
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
61Subventions
Organisme : the Medical Science and Technology Research Fund of Guangdong Province
ID : A2020374
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Santucci C, Carioli G, Bertuccio P, Malvezzi M, Pastorino U, Boffetta P, Negri E, Bosetti C, La Vecchia C (2020) Progress in cancer mortality, incidence, and survival: a global overview. European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP) 29(5):367–381
doi: 10.1097/CEJ.0000000000000594
pubmed: 32740162
Lotfollahzadeh S, Recio-Boiles A, Cagir B (2022) Colon cancer. In: StatPearls. edn. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC 3
Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33
doi: 10.3322/caac.21708
pubmed: 35020204
Pomeroy AE, Schmidt EV, Sorger PK, Palmer AC (2022) Drug independence and the curability of cancer by combination chemotherapy. Trends Cancer 8(11):915–929
doi: 10.1016/j.trecan.2022.06.009
pubmed: 35842290
Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S et al (2017) Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial. JAMA Oncol 3(11):1538–1545
doi: 10.1001/jamaoncol.2017.1269
pubmed: 28715540
pmcid: 5710192
Lu W, Huang Z, Chen S, Lv H, Chen X, Lei J, Ke C, Hong C, Wei Y, Su R et al (2021) The effectiveness of EVOSKIN®Palm and sole moisturizing cream in treating capecitabine-associated hand-foot syndrome: a randomized double-blind clinical trial. Ann Palliat Med 10(3):3009–3017
doi: 10.21037/apm-21-61
pubmed: 33849091
Kwakman JJM, Simkens LHJ, van Rooijen JM, van de Wouw AJ, Ten Tije AJ, Creemers GJM, Hendriks MP, Los M, van Alphen RJ, Polée MB et al (2017) Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group. Annals of Oncology : Official Journal of the European Society for Medical Oncology 28(6):1288–1293
doi: 10.1093/annonc/mdx122
pubmed: 28383633
Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, Erdkamp FL, Erjavec Z, van der Torren AM et al (2015) Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 385(9980):1843–1852
doi: 10.1016/S0140-6736(14)62004-3
pubmed: 25862517
Zhao Y, Ding Y, Lu Y, Zhang J, Gu J, Li M (2013) Incidence and self-management of hand-foot syndrome in patients with colorectal cancer. Clin J Oncol Nurs 17(4):434–437
doi: 10.1188/13.CJON.434-437
pubmed: 23899983
Son HS, Lee WY, Lee WS, Yun SH, Chun HK (2009) Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy. Yonsei Med J 50(6):796–802
doi: 10.3349/ymj.2009.50.6.796
pubmed: 20046420
pmcid: 2796406
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C (2015) Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. Int J Evid Based Healthc 13(3):147–153
doi: 10.1097/XEB.0000000000000054
pubmed: 26317388
Wu J, Wang Z, Jin C, Ren H, Hu Y, Yang B, Hu Y (2021) Effect of cetuximab combined with chemotherapy in treating metastatic colorectal cancer and its prognostic analysis. J BUON 26(1):101–108
pubmed: 33721439
Pietrantonio F, Lobefaro R, Antista M, Lonardi S, Raimondi A, Morano F, Mosconi S, Rimassa L, Murgioni S, Sartore-Bianchi A et al (2020) Capecitabine and temozolomide versus FOLFIRI in RAS-mutated, MGMT-methylated metastatic colorectal cancer. Clin Cancer Res 26(5):1017–1024
doi: 10.1158/1078-0432.CCR-19-3024
pubmed: 31740551
Mizumoto Y, Yokoyama S, Matsuda K, Iwamoto H, Mitani Y, Tamura K, Nakamura Y, Murakami D, Oka M, Kobayashi Y et al (2020) Modulation of capecitabine administration to improve continuity of adjuvant chemotherapy for patients with colorectal cancer: a phase II study. Mol Clin Oncol 12(2):126–133
pubmed: 31929883
Guo Y, Zheng T, Zhang C, Zhang Y (2020) A study of the S-1 or capecitabine as first-line regimen in patients with metastatic colorectal cancer: a real world study. J Cancer 11(7):1839–1845
doi: 10.7150/jca.36929
pubmed: 32194795
pmcid: 7052859
Yamazaki K, Matsumoto S, Imamura CK, Yamagiwa C, Shimizu A, Yoshino T (2019) Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study. Jpn J Clin Oncol 50(2):122–128
Xu JL, Tang CW, Feng WM, Bao Y, Chai ZZ (2019) Prolonged capecitabine chemotherapy following capecitabine and oxaliplatin (CAPOX) regimen chemotherapy failed to improve survival of stage III colorectal cancer after radical resection. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research 25:4831–4836
doi: 10.12659/MSM.915992
pubmed: 31254462
Sánchez-Gundín J, Torres-Suárez AI, Fernández-Carballido AM, Barreda-Hernández D (2019) Capecitabine safety profile, innovative and generic adjuvant formulation of nonmetastatic colorectal cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 43(5):158–162
pubmed: 31469628
Lu CX, Zheng BW, Bai B, Hu JL, Fan SF, Shang DF, Yang D, Zhao CL, Cang SD (2019) Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology] 41(9):708–711
pubmed: 31550863
Suenaga M, Akiyoshi T, Shinozaki E, Fujimoto Y, Matsusaka S, Konishi T, Nagayama S, Fukunaga Y, Kawakami K, Yokokawa T et al (2018) A feasibility study of capecitabine and oxaliplatin for patients with stage II/III colon cancer -ACTOR study. Anticancer Res 38(3):1741–1747
pubmed: 29491111
Peng J, Li W, Zhang R, Lin J, Tang J, Wen Y, Lu Z, Wu X, Pan Z (2019) Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience. Cancer Commun 39(1)
Kusumoto T, Sunami E, Ota M, Yoshida K, Sakamoto Y, Tomita N, Maeda A, Mochizuki I, Okabe M, Kunieda K et al (2018) Planned safety analysis of the ACTS-CC 02 trial: a randomized phase III trial of S-1 with oxaliplatin versus tegafur and uracil with leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer. Clin Colorectal Cancer 17(2):e153–e161
doi: 10.1016/j.clcc.2017.10.015
pubmed: 29249584
Suto T, Ishiguro M, Hamada C, Kunieda K, Masuko H, Kondo K, Ishida H, Nishimura G, Sasaki K, Morita T et al (2017) Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer. Int J Clin Oncol 22(3):494–504
doi: 10.1007/s10147-016-1083-9
pubmed: 28078540
pmcid: 5486458
Emi Y, Kakeji Y, Oki E, Saeki H, Ando K, Kitazono M, Sakaguchi Y, Morita M, Samura H, Ogata Y et al (2013) Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients. Int J Clin Oncol 18(2):254–259
doi: 10.1007/s10147-011-0371-7
pubmed: 22240888
Hong YS, Park YS, Lim HY, Lee J, Kim TW, Kim KP, Kim SY, Baek JY, Kim JH, Lee KW et al (2012) S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol 13(11):1125–1132
doi: 10.1016/S1470-2045(12)70363-7
pubmed: 23062232
Law CC, Fu YT, Chau KK, Choy TS, So PF, Wong KH (2007) Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with stage III colon cancer. Dis Colon Rectum 50(12):2180–2187
doi: 10.1007/s10350-007-9045-y
pubmed: 17963003
Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G et al (2004) Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer 100(2):279–287
doi: 10.1002/cncr.11910
pubmed: 14716761
Abushullaih S, Saad ED, Munsell M, Hoff PM (2002) Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 20(1):3–10
doi: 10.1081/CNV-120000360
pubmed: 11853000
Chiara S, Nobile MT, Barzacchi C, Sanguineti O, Vincenti M, Di Somma C, Meszaros P, Rosso R (1997) Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 33(6):967–969
doi: 10.1016/S0959-8049(96)00497-2
pubmed: 9291822
Nakamura N, Shiraiwa H, Haruna Y, Ichijima T, Takeda T, Hasegawa K, Kusumoto M, Yano Y (2021) Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand–foot syndrome in cancer patients: a retrospective study. J Pharm Health Care Sci 7(1)
Chen J, Wang B, Yin X, Liang Q, Li Y, Xie X, Zeng X (2022) Application value of nutrition support team in chemotherapy period of colon cancer based on internet multidisciplinary treatment mode. Comput Math Methods Med 2022
Ye JX, Liu AQ, Ge LY, Zhou SZ, Liang ZG (2014) Effectiveness and safety profile of S-1-based chemotherapy compared with capecitabine-based chemotherapy for advanced gastric and colorectal cancer: a meta-analysis. Exp Ther Med 7(5):1271–1278
doi: 10.3892/etm.2014.1576
pubmed: 24940424
pmcid: 3991506
Punt CJA, Kwakman JJM, Mol L (2022) Long-term safety data on S-1 administered after previous intolerance to capecitabine-containing systemic treatment for metastatic colorectal cancer. Clin Colorectal Cancer 21(3):229–235
doi: 10.1016/j.clcc.2022.02.004
pubmed: 35341693
Xu J, Lin Z, Chen J, Zhang J, Li W, Zhang R, Xing J, Ye Z, Liu X, Gao Q et al (2022) Milk and egg are risk factors for adverse effects of capecitabine-based chemotherapy in Chinese colorectal cancer patients. Integr Cancer Ther 21:15347354221105484
doi: 10.1177/15347354221105485
pubmed: 35686441
pmcid: 9189551
Jiang M, Ding G, Li G (2021) Diagnostic value of combined detection of multiple tumor markers and blood lipid indexes in colorectal cancer and its prediction on adverse reactions of chemotherapy. J BUON 26(4):1226–1230
pubmed: 34564974
Baack BR, Burgdorf WH (1991) Chemotherapy-induced acral erythema. J Am Acad Dermatol 24(3):457–461
doi: 10.1016/0190-9622(91)70073-B
pubmed: 2061446
Tsuboi H, Yonemoto K, Katsuoka K (2005) A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature. J Dermatol 32(11):921–925
doi: 10.1111/j.1346-8138.2005.tb00873.x
pubmed: 16361756
Yoshida Y, Sasaoka S, Tanaka M, Matsumoto K, Inoue M, Satake R, Shimada K, Mukai R, Suzuki T, Iwata M et al (2022) Analysis of drug-induced hand-foot syndrome using a spontaneous reporting system database. Ther Adv Drug saf 13:20420986221101964
doi: 10.1177/20420986221101963
pubmed: 35646307
pmcid: 9136434
Murugan K, Ostwal V, Carvalho MD, D’Souza A, Achrekar MS, Govindarajan S, Gupta S (2016) Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer 24(6):2575–2581
doi: 10.1007/s00520-015-3061-6
pubmed: 26715292
Zaiem A, Hammamia SB, Aouinti I, Charfi O, Ladhari W, Kastalli S, Aidli SE, Lakhoua G (2022) Hand-foot syndrome induced by chemotherapy drug: case series study and literature review. Indian J Pharmacol 54(3):208–215
pubmed: 35848692
pmcid: 9396690
Liu Y, May BH, Zhang AL, Guo X, Lu C, Xue CC, Zhang H (2019) Integrative herbal medicine for chemotherapy-induced peripheral neuropathy and hand-foot syndrome in colorectal cancer: a systematic review and meta-analysis. Integr Cancer Ther 18:1534735418817833
doi: 10.1177/1534735418817833
pubmed: 30526124
Meng W, Zeng X, Gao Y, Chen Q, Bai L (2021) Efficacy of Aidi injection and Brucea javanica oil emulsion injection in rectal cancer during CapeOX adjuvant chemotherapy. Biomed Res Int 2021:2033353
doi: 10.1155/2021/2033353
pubmed: 34765675
pmcid: 8577932
Lan TC, Tsou PH, Tam KW, Huang TW (2022) Effect of urea cream on hand-foot syndrome in patients receiving chemotherapy a meta-analysis. Cancer Nurs 45(5):378–386
doi: 10.1097/NCC.0000000000001008
pubmed: 34483284
Iimura Y, Furukawa N, Ishibashi M, Ahiko Y, Tanabe T, Aikou S, Shida D, Nojima M, Kuroda S, Boku N (2022) Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study). BMC Gastroenterol 22(1):341
doi: 10.1186/s12876-022-02411-w
pubmed: 35836104
pmcid: 9284769